WO2005103231A3 - Cellules dendritiques chargees de substances toxiques destinees au traitement de carcinomes de cellules hepatiques - Google Patents

Cellules dendritiques chargees de substances toxiques destinees au traitement de carcinomes de cellules hepatiques Download PDF

Info

Publication number
WO2005103231A3
WO2005103231A3 PCT/DE2005/000719 DE2005000719W WO2005103231A3 WO 2005103231 A3 WO2005103231 A3 WO 2005103231A3 DE 2005000719 W DE2005000719 W DE 2005000719W WO 2005103231 A3 WO2005103231 A3 WO 2005103231A3
Authority
WO
WIPO (PCT)
Prior art keywords
kidney cell
cell carcinomas
order
toxic substances
treat kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2005/000719
Other languages
German (de)
English (en)
Other versions
WO2005103231A2 (fr
Inventor
Dirk Weickmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toximed GmbH
Original Assignee
Toximed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toximed GmbH filed Critical Toximed GmbH
Priority to DE112005001476T priority Critical patent/DE112005001476A5/de
Publication of WO2005103231A2 publication Critical patent/WO2005103231A2/fr
Anticipated expiration legal-status Critical
Publication of WO2005103231A3 publication Critical patent/WO2005103231A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un agent pharmaceutique destiné au traitement de carcinomes de cellules hépatiques à l'aide de cellules dendritiques cultivées en présence de leukine, et chargées de toxines provenant du venin des araignées du type Loxosceles, Scytodiae ou Drymusa. L'invention concerne également des procédés de fabrication desdites cellules dendritiques.
PCT/DE2005/000719 2004-04-21 2005-04-20 Cellules dendritiques chargees de substances toxiques destinees au traitement de carcinomes de cellules hepatiques Ceased WO2005103231A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE112005001476T DE112005001476A5 (de) 2004-04-21 2005-04-20 Mit toxischen Substanzen beladene dendritische Zellen zur Behandlung von Nierenzellkarzinomen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004019323.1 2004-04-21
DE102004019323A DE102004019323A1 (de) 2004-04-21 2004-04-21 Mit toxischen Substanzen beladene dendritische Zellen zur Behandlung von Nierenzellkarzinomen

Publications (2)

Publication Number Publication Date
WO2005103231A2 WO2005103231A2 (fr) 2005-11-03
WO2005103231A3 true WO2005103231A3 (fr) 2006-12-28

Family

ID=34993192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2005/000719 Ceased WO2005103231A2 (fr) 2004-04-21 2005-04-20 Cellules dendritiques chargees de substances toxiques destinees au traitement de carcinomes de cellules hepatiques

Country Status (2)

Country Link
DE (2) DE102004019323A1 (fr)
WO (1) WO2005103231A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001823A2 (fr) * 1998-07-02 2000-01-13 Immunex Corporation Mutants flt3-l et leur utilisation
WO2001043754A2 (fr) * 1999-12-17 2001-06-21 Mack, Gerd, R. Preparation pharmaceutique a base de venin d'araignee, sa preparation et son utilisation pour traiter des affections tumorales
WO2001087346A2 (fr) * 2000-05-17 2001-11-22 Toximed Gmbh Cellules dendritiques chargees de substances toxiques
WO2001088105A2 (fr) * 2000-05-17 2001-11-22 Toximed Gmbh Production de cellules dendritiques issues de cellules souches de la moelle osseuse
WO2003006055A2 (fr) * 2001-05-14 2003-01-23 Duotol Ab Procedes permettant de favoriser la presentation de l'antigene et de la modulation de reponses immunitaires au moyen de toxines du cholera et son sous-unite b
WO2004053095A2 (fr) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. Maturation in situ de cellules dendritiques
WO2004074451A2 (fr) * 2003-02-18 2004-09-02 Maxcyte, Inc. Introduction d'antigenes dans des cellules par electroporation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001823A2 (fr) * 1998-07-02 2000-01-13 Immunex Corporation Mutants flt3-l et leur utilisation
WO2001043754A2 (fr) * 1999-12-17 2001-06-21 Mack, Gerd, R. Preparation pharmaceutique a base de venin d'araignee, sa preparation et son utilisation pour traiter des affections tumorales
WO2001087346A2 (fr) * 2000-05-17 2001-11-22 Toximed Gmbh Cellules dendritiques chargees de substances toxiques
WO2001088105A2 (fr) * 2000-05-17 2001-11-22 Toximed Gmbh Production de cellules dendritiques issues de cellules souches de la moelle osseuse
WO2003006055A2 (fr) * 2001-05-14 2003-01-23 Duotol Ab Procedes permettant de favoriser la presentation de l'antigene et de la modulation de reponses immunitaires au moyen de toxines du cholera et son sous-unite b
WO2004053095A2 (fr) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. Maturation in situ de cellules dendritiques
WO2004074451A2 (fr) * 2003-02-18 2004-09-02 Maxcyte, Inc. Introduction d'antigenes dans des cellules par electroporation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCI MOWAT A ET AL: "ORAL VACCINATION WITH IMMUNE STIMULATING COMPLEXES", IMMUNOLOGY LETTERS, AMSTERDAM, NL, vol. 65, 1999, pages 133 - 140, XP002906832, ISSN: 0165-2478 *

Also Published As

Publication number Publication date
WO2005103231A2 (fr) 2005-11-03
DE102004019323A1 (de) 2005-11-10
DE112005001476A5 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2006113679A3 (fr) Administration d'arnsi par compositions lipidiques neutres
WO2007024705A3 (fr) Procede de traitement de la depression au moyen d'un anticorps anti-tnf-alpha
GB0621241D0 (en) Ion binding compositions
WO2007022519A3 (fr) Lesions orientables excluant des implants cardiaques d'insuffisance cardiaque congestive
WO2008082669A3 (fr) Conjugués polymère-facteur viii et facteur von willebrand comprenant une liaison dégradable
WO2004081185A3 (fr) Procede permettant d'ameliorer l'activite d'enzymes de degradation de la lignocellulose
WO2002024865A3 (fr) Modulation de production de metabolites secondaires par des proteines en bouquet binucleaire a zinc
WO2007033281A3 (fr) Résine échangeuse d’ions traitée en vue de contrôler le gonflement
WO2008027420A3 (fr) Dispositifs implantables pour la production d'insuline
WO2009100194A3 (fr) Conjugués à fraction de liaison à la camptothécine
WO2007117490A3 (fr) Purification d'anticorps
WO2007011390A3 (fr) Production a grande echelle de butyrylcholinesterase de serum humain comme accepteur biologique
WO2006076651A3 (fr) Procede de traitement
WO2007002376A3 (fr) Procede de preparation d'electrode
WO2007027999A3 (fr) Composes chimiques
WO2006009765A3 (fr) Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments
WO2007076085A3 (fr) Pyrimidones et thiopyrimidones fusionnees et leurs utilisations
WO2005108428A3 (fr) Variants d'epissage de cd40 et leurs utilisations
WO2005095652A3 (fr) Pnmt en tant que nouveau marqueur de cellules progenitrices
WO2009023544A3 (fr) Compositions pharmaceutiques à base de polymères échangeurs d'anions en dose
WO2010032008A3 (fr) Molécule modulatrice des cellules dendritiques
WO2007019865A3 (fr) Traitement au moyen de peptides de liaison cd4 et par rayonnements
WO2008107471A3 (fr) Conjugués d'hydroxypolymère modifié à activité destructrice de cellules tumorales
WO2005017100A8 (fr) Ribonucleases et procedes de production de ribonucleases par recombinaison
WO2006071746A3 (fr) Neurones de dopamine modifies et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1120050014762

Country of ref document: DE

122 Ep: pct application non-entry in european phase
REF Corresponds to

Ref document number: 112005001476

Country of ref document: DE

Date of ref document: 20070524

Kind code of ref document: P